ATE393243T1 - Diagnostisches verfahren der mastozytose - Google Patents

Diagnostisches verfahren der mastozytose

Info

Publication number
ATE393243T1
ATE393243T1 AT04715423T AT04715423T ATE393243T1 AT E393243 T1 ATE393243 T1 AT E393243T1 AT 04715423 T AT04715423 T AT 04715423T AT 04715423 T AT04715423 T AT 04715423T AT E393243 T1 ATE393243 T1 AT E393243T1
Authority
AT
Austria
Prior art keywords
mastocytosis
mutation
detected
kit
diagnostic procedure
Prior art date
Application number
AT04715423T
Other languages
English (en)
Inventor
Jean-Pierre Kinet
Alain Moussy
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Application granted granted Critical
Publication of ATE393243T1 publication Critical patent/ATE393243T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04715423T 2003-02-27 2004-02-27 Diagnostisches verfahren der mastozytose ATE393243T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44986103P 2003-02-27 2003-02-27

Publications (1)

Publication Number Publication Date
ATE393243T1 true ATE393243T1 (de) 2008-05-15

Family

ID=32927581

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04715423T ATE393243T1 (de) 2003-02-27 2004-02-27 Diagnostisches verfahren der mastozytose

Country Status (7)

Country Link
US (1) US20080025916A1 (de)
EP (1) EP1597398B1 (de)
JP (1) JP2006519220A (de)
AT (1) ATE393243T1 (de)
CA (1) CA2517308A1 (de)
DE (1) DE602004013283D1 (de)
WO (1) WO2004076693A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2535242A1 (en) * 2003-08-15 2005-02-24 Ab Science Use of c-kit inhibitors for treating type ii diabetes
PL1684750T3 (pl) 2003-10-23 2010-10-29 Ab Science 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej
EP2361624A1 (de) * 2005-04-04 2011-08-31 AB Science Oxazolderivate und Ihre Anwendung als Tyrosinkinase Inhibitoren
SG159561A1 (en) 2005-05-09 2010-03-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
CN103342701B (zh) 2007-02-13 2016-09-21 Ab科学有限公司 作为激酶抑制剂的2-氨基噻唑化合物多晶型及其制备方法
US8183263B2 (en) 2007-05-22 2012-05-22 Achillion Pharmaceuticals, Inc. Heteroaryl substituted thiazoles
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339100B1 (en) * 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
EP1471907B1 (de) * 2001-06-29 2008-07-16 AB Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
US20050054617A1 (en) * 2001-06-29 2005-03-10 Alain Moussy Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
CA2452390A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating bone loss
EP1434991B1 (de) * 2001-06-29 2007-10-17 AB Science C-kit inhibitoren
DE60316810T2 (de) * 2002-08-02 2008-07-17 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren

Also Published As

Publication number Publication date
CA2517308A1 (en) 2004-09-10
US20080025916A1 (en) 2008-01-31
JP2006519220A (ja) 2006-08-24
EP1597398B1 (de) 2008-04-23
WO2004076693A1 (en) 2004-09-10
DE602004013283D1 (de) 2008-06-05
EP1597398A1 (de) 2005-11-23

Similar Documents

Publication Publication Date Title
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
Cunningham et al. Development of a condition‐specific quality of life measure for patients with dentofacial deformity: II. Validity and responsiveness testing
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE447878T1 (de) Verfahren und vorrichtung zur augenverfolgung
ATE403750T1 (de) Methoden und kompositionen zur bewertung von antikörper behandlungen
ATE311876T1 (de) Hochselektive butyrylcholinesterase inhibitoren zur behandlung und zur diagnose von demenz und alzheimers krankheit
WO2006041678A3 (en) Pharmaceutical treatment effectiveness analysis computer system and methods
WO2003107252A3 (en) METHOD AND SYSTEM FOR MONITORING PATIENT CARE
DE69434152D1 (de) Vorrichtung zur beurteilungshilfe des kardiovaskulären zustandes eines patienten
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
CY1110503T1 (el) Πενταμιδινη για θεραπεια καρκινου
DE60324925D1 (de) Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
DE602004013283D1 (de) Diagnostisches verfahren der mastozytose
ATE557087T1 (de) Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
SE0301825D0 (sv) Method and arrangement relating to testing implants
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
FI933291A0 (fi) Foerfarande foer paovisning av anti-rna-antikroppar
DE60231896D1 (de) Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
ATE430517T1 (de) Verfahren und geräte zur beobachtung und aufzeichnung von unregelmässigkeiten der makula und des nahen retinafelds
DE602006005635D1 (de) Vorrichtung und verfahren zum automatischen prüfen der temperaturempfindlichkeit eines patienten
AU2579995A (en) Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
EP1611251A4 (de) Therapeutische, prophylaktische und diagnostische wirkstoffe
ATE556053T1 (de) Piperidinderivate zur behandlung von alzheimer- krankheit
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties